EAP: donnes factuelles de la litrature ? M Sapoval,, O Pellerin, C - - PowerPoint PPT Presentation

▶
eap donn es factuelles de la lit rature
SMART_READER_LITE
LIVE PREVIEW

EAP: donnes factuelles de la litrature ? M Sapoval,, O Pellerin, C - - PowerPoint PPT Presentation

Nov 24, 2023 586 likes •1.06k views

EAP: donnes factuelles de la litrature ? M Sapoval,, O Pellerin, C Del Giudice N Thiounn P Meria Vascular and Oncological Interventional Radiology Urology HEGP et St Louis Hpital Europen Georges Pompidou Universit Paris Rene

slide-1
SLIDE 1

EAP: données factuelles de la litérature ?

M Sapoval,, O Pellerin, C Del Giudice N Thiounn P Meria Vascular and Oncological Interventional Radiology Urology HEGP et St Louis Hôpital Européen Georges Pompidou Université Paris Renée Descartes

slide-2
SLIDE 2

Conflit d’Intéret

Consultant Merit Médical Europeen training center.

slide-3
SLIDE 3

Ca marche ?

  • Rétentions aigues d’urines
  • Oui ……
  • SBAU en rapport avec une HBP
  • Oui ….
slide-4
SLIDE 4

Level of Current Evidence Level 1

Plus de 100 peer reviewed papers Mid and long term follow up in 1000 cases x 4 RCTS from China, Brazil, Switzerland Spanish RCT presented CIRSE 2018 submitted for publication. Large Multi-centre Registry from UK x 3 Systematic Reviews Meta-analysis

slide-5
SLIDE 5

RCT China results

Gao et al Radiology 2014 270(3);920-928

slide-6
SLIDE 6
slide-7
SLIDE 7

Sao Paulo Group 12 month Results

TURP

  • PAE

PErFecTED IPSS 6.1 12.8 3.6 QoL 0.9 2.2 1.6 IIEF 16.1 12.6 18.7 Prostate Volume 32 50.9 50 PSA 1.6 2.2 1.7 PVR 8.3 62.3 48.6 Qmax 27.1 10.1 16.7 Carnevale et al. CVIR 2015

slide-8
SLIDE 8

Swiss RCT published in BMJ June 2018

Dominik Abt, Lukas Hechelhammer et al Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial

slide-9
SLIDE 9
slide-10
SLIDE 10

UK-ROPE

slide-11
SLIDE 11
slide-12
SLIDE 12
slide-13
SLIDE 13
slide-14
SLIDE 14

Rétentions aigues d’urine

Le premier traitement de la RAU Alpha-bloquants 48 h Retrait de la sonde En cas d’échec de désondage ...

slide-15
SLIDE 15

Clinical failure at 6m follow-up after PAE n = 6 (30%) Clinical success at 6m follow up after PAE n = 14 (70%) AUR + TWOC failure n = 20 pts Successfull BIC removal after PAE n = 15 (75%) Failure to remove BIC after PAE n = 5 (25%) No recatheterization event n = 13 pts Recatheterization event Free of IBC thereafter n = 1 Recatheterization event Failed to void independently thereafter n = 1

*14 patients (70%) achieved spontaneous voiding during the first attempt to remove the IBC at 15 ± 3 days after PAE

Kenny A, Sapoval M Am J Med. 2019 May 16.

slide-16
SLIDE 16

Previous authors: different methodological approach and/or PAE technique

  • All single center studies
  • Definition of clinical success and follow-up after PAE differs between studies
  • All of them used Embospheres (size varied between 100-300 µm, 300-500 µm)
  • Only two of them attempted to perform the PErFecTED technique (no success % reported)
  • Policy regarding BPH medication discontinuation varies greatly between studies
  • Our group of patients has a mean PV bigger than the majority of the others studies and a

significant shorter mean duration of catheter indwell before PAE

slide-17
SLIDE 17

Ca marche longtemps ?

Oui

slide-18
SLIDE 18

Résultats à long terme (1)

  • 10%-30% of clinical failures
  • Non-responders (80%) Vs Relapsers (20%)
slide-19
SLIDE 19

Kenny AG, Pellerin O, Moussa N, Del Giudice C, Amouyal G, Déan C, Thiounn N, Sapoval M Kenny AG, Kenny AG, Pellerin O, Moussa N, Del Giudice C, Amouyal G, Pellerin O, Moussa N, Del Giudice C, Amouyal G, D Dé éan C, Thiounn N, Sapoval M an C, Thiounn N, Sapoval M

slide-20
SLIDE 20

How we did it? cohort of 44 consecutive Between December 2013 and July 2015:

  • 47 consecutive PAEs
  • All of them were refered to the interventional radiology departement after intolerance or

failure of medical treatment for at least 6 month and refusal of surgery

  • The medical records were reviewed from our database
  • Complications* and further BPH invasive treatments after PAE were recorded
  • A phone interview was conducted to assess patient’s experience
  • 3 patients were lost to follow-up, they were excluded from the study
  • Our study group consisted of 44 patients

* Complications were defined according to the SIR classification

Long-Term Patient’s Experience After Prostatic Artery Embolization

slide-21
SLIDE 21

How we did it? Les patients opérés étaient définis comme échec Clinique Les autres interview teléphonique standardisé: (1) avez vous des SBAU ? (2) prenez vous un tt ? (3) le referiez vous ? (4) le recommenderiez vous à vos proches

Long-Term Patient’s Experience After Prostatic Artery Embolization

slide-22
SLIDE 22

Long-Term Patient’s Experience After Prostatic Artery Embolization

slide-23
SLIDE 23

Ca marche toujours ?

  • Non ……
  • Environ 20 % de non répondeurs:

– Echec clinique – Malgré succès technique

slide-24
SLIDE 24

Non-repondeurs ?

  • 1. Patient characteristics:
  • Age?
  • Prostate vascularity?
  • Prostate volume? Median lobe?
  • Peak urinary flow-rate (Qmax) /post-void residual urine

(PVR) – bladder function?

  • Symptom severity?
  • Acute urinary retention?
  • 2. Technique
  • Uni/Bilateral?
  • Embolic agent/size
slide-25
SLIDE 25

Que faire si echec

  • Si échec technique
  • Nouvelle tentative
  • Si échec clinique
  • Discuter ré embolisation
  • Discuter chirurgie
  • Discuter traitement médical renforcé ?
  • Utiliser les bons mots….
  • amélioration insuffisante ?
  • aucune amélioration (non repondeur)
  • échec initial mais récidive ( « relapser »)
slide-26
SLIDE 26

How can PAE fail ?

M Sapoval, GEST 2019

slide-27
SLIDE 27

Case of non responder

  • Before PAE
  • PV 75 ml
  • IPSS 28
  • QOL 6
  • 12m after PAE
  • PV: 75 ml
  • IPSS 23
  • QOL 6
slide-28
SLIDE 28

How can PAE fail ?

M Sapoval, GEST 2019

slide-29
SLIDE 29

MRI at 12 months 70 ml

slide-30
SLIDE 30

Right Left first PAE Left re PAE Right first PAE Smaller PA Less blush Rectal anast. Right re PAE Smaller PA Less blush

slide-31
SLIDE 31

d c e f g h i

How to manage ?

Right side: go distal left side go distal embolize through a neo-anastomosis (internal pudendal)

slide-32
SLIDE 32

Follow up

  • 6 m POST PArE
  • IPSS 1
  • QOL 1
  • Take home:
  • Clinical failure can be explained by revascularisation by
  • Native PA
  • Collateral (internal pudendal)
  • In case of clinical failure a redo is an option
slide-33
SLIDE 33

Insuficient improvment

slide-34
SLIDE 34

a b d e c

slide-35
SLIDE 35

Outcome of re embo

slide-36
SLIDE 36

Points techniques …

  • Taille des billes ?
  • Matériel d’embolisation ?
  • Unilateral ou bilatéral ?
slide-37
SLIDE 37

Role de la technique ?

  • Embolisation Unilatérale ?

– moins bon résultats

  • Sur le désondage
  • Sur la réduction d’IPSS

– Toujours bilatérale – Taille des particules ?

slide-38
SLIDE 38

Particle size matters?

slide-39
SLIDE 39

Particle size matters? More “aggressive” embolization?

  • PAE with smaller PVA particles

(50µm + 100µm) had better

  • utcomes

Before 1 week 12 months 50µm + 100µm 100µm

slide-40
SLIDE 40

Particle size matters?

  • PAE with smaller PVA particles

(100µm) had worse outcomes than with larger (200µm)

slide-41
SLIDE 41

Taille des particules

  • Embosphere

– 300 -500 µm mieux que 100-300 µm – Plus de complications avec les 100-300 µm

  • PVA

– 50 µm puis 100 µm fait mieux que 100 µm … – 200 µm fait mieux que 100 µm … – ??

  • Notre choix: Embosphere 300 -500 µm
slide-42
SLIDE 42

Do technical outcomes translate into clinical outcomes?

  • Clinical success:

– Bilateral PAE – 75% – Unilateral PAE – 50% - older patients

2012

slide-43
SLIDE 43

Benign Prostatic Hyperplasia

Place of PAE among BPH treatments

surveillance herbs 5 ARI Alpha blockers Radio frequency Surgery/laser PAE ?

BPH symptoms

slide-44
SLIDE 44

12/09/2018 - MEP v1-3 15MSL-PARTEM - URC HEGP CIC EC

PARTEM

Embolisation des artères prostatiques versus traitement médical dans l'hyperplasie bénigne de la prostate

Investigateur coordonnateur : Pr Marc Sapoval – Service de radiologie interventionnelle Hôpital Européen Georges Pompidou (HEGP) Pr Nicolas Thiounn , Urologie (Pr Méjean, HEGP) Promoteur : Assistance Publique-Hôpitaux de Paris Département de la Recherche Clinique et de l’Innovation

44/67

slide-45
SLIDE 45

12/09/2018 - MEP v1-3 15MSL-PARTEM - URC HEGP CIC EC

Objectif et critère de jugement principal

  • Objectif principal : Comparer les effets à 9 mois sur les SBAU
  • de l’Embolisation
  • versus Thérapie Combinée (alpha-bloquant + inhibiteur de la 5

alpha-réductase)

  • Critère de jugement principal : IPSS 9 mois après la randomisation

45/67

slide-46
SLIDE 46

12/09/2018 - MEP v1-3 15MSL-PARTEM - URC HEGP CIC EC

Schéma du déroulement de la recherche pour le sujet

46/67

slide-47
SLIDE 47

Conclusion

  • Oui ca marche ….
  • Oui c’est difficile …
  • Non on ne connaît pas encore

– Les bons répondeurs ? – Les résultats contre placebo (sham) ? – La place de l’EAP par rapport au traitement médical – La place de l’EAP par rapport au TK mini-invasives